SCHEMBL924382

SCHEMBL924382

CCc1ncc(Cc2ccccc2)cc1C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HNF4A P41235 1/20 0.50
PTPN1 P18031 4/20 0.48
PTPN2 P17706 2/20 0.48
PTPN6 P29350 2/20 0.48
ALDH1A1 P00352 1/20 0.43
HPGD P15428 1/20 0.43
HTT P42858 1/20 0.43
ACMSD Q8TDX5 1/20 0.41
NPC1 O15118 1/20 0.41
KDM4E B2RXH2 3/20 0.41
ASPH Q12797 3/20 0.41
RIOX2 Q8IUF8 3/20 0.41
KDM8 Q8N371 3/20 0.41
KDM4A O75164 1/20 0.41
KDM5A P29375 1/20 0.41
KDM4C Q9H3R0 1/20 0.41
KDM5B Q9UGL1 1/20 0.41
MTNR1A P48039 1/20 0.40
MTNR1B P49286 1/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13850877 0.80 HNF4A (0.54) HNF4APTPN1PTPN2PTPN6ALDH1A1
SCHEMBL11630337 0.77 PTPN1 (0.45) HNF4APTPN1PTPN2PTPN6ALDH1A1
SCHEMBL13851063 0.76 KDM4E (0.46) HNF4APTPN1PTPN2PTPN6ALDH1A1
SCHEMBL19857480 0.74 GABRP (0.46) ALDH1A1NPC1KDM4EGABRPGABRD
SCHEMBL11623244 0.74 GABRP (0.46) ALDH1A1HPGDNPC1KDM4EGABRP
SCHEMBL13851064 0.73 KDM4E (0.48) ALDH1A1NPC1KDM4ELMNAGABRA1
SCHEMBL23566852 0.72 AGBL2 (0.51) NPC1KDM4EASPHKDM8KDM4C
SCHEMBL924177 0.72 GABRP (0.45) ALDH1A1HTTNPC1KDM4EGABRP
SCHEMBL24365134 0.72 GABRP (0.53) PTPN1ALDH1A1HPGDNPC1KDM4E
SCHEMBL11630841 0.72 RNASEH1 (0.42) HNF4APTPN1PTPN2PTPN6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163766-B2 Beta-secretase modulators and methods of use AMGEN INC. (US) 2012-04-24 US disclosed
US-20110118250-A1 BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2011-05-19 US disclosed
US-7872009-B2 Beta-Secretase modulators and methods of use AMGEN INC. (US) 2011-01-18 US disclosed
EP-1954693-A1 BETA-SECRETASE MODULATORS AND METHODS OF USE Amgen Inc. (US) 2008-08-13 EP disclosed
US-20070185103-A1 Beta-secretase modulators and methods of use AMGEN INC. 2007-08-09 US disclosed
WO-2007062007-A1 BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2007-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118250-A1 BETA-SECRETASE MODULATORS AND METHODS OF USE BACE1, BACE2, APP HNF4A 2609/4885PTPN1 4582/4885PTPN2 4621/4885
US-20070185103-A1 Beta-secretase modulators and methods of use BACE1, BACE2, APP HNF4A 2609/4885PTPN1 4582/4885PTPN2 4621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.